Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 10,879,000 | 11,207,000 | 10,982,000 | 10,771,000 | 11,390,000 |
| Cost of Goods | 1,905,000 | 2,900,000 | 2,982,000 | 2,998,000 | 3,511,000 |
| Gross Profit | 8,974,000 | 8,307,000 | 8,000,000 | 7,773,000 | 7,879,000 |
| Operating Expenses | 6,666,000 | 7,978,000 | 6,591,000 | 7,234,000 | 7,001,000 |
| Operating Income | 2,308,000 | 329,000 | 1,409,000 | 539,000 | 878,000 |
| Interest Expense | 365,000 | 344,000 | 339,000 | 311,000 | 336,000 |
| Other Income | 319,000 | 793,000 | -148,000 | 19,000 | 11,000 |
| Pre-tax Income | 2,262,000 | 778,000 | 922,000 | 247,000 | 553,000 |
| Income Tax | 458,000 | -124,000 | -720,000 | -113,000 | 165,000 |
| Net Income Continuous | 1,804,000 | 902,000 | 1,642,000 | 360,000 | 388,000 |
| Minority Interests | -1,000 | -1,000 | -2,000 | 0 | -2,000 |
| Net Income | $1,803,000 | $901,000 | $1,640,000 | $360,000 | $386,000 |
| EPS Basic Total Ops | 1.16 | 0.58 | 1.06 | 0.23 | 0.25 |
| EPS Basic Continuous Ops | 1.16 | 0.58 | 1.06 | 0.23 | 0.25 |
| EPS Diluted Total Ops | 1.16 | 0.58 | 1.05 | 0.23 | 0.25 |
| EPS Diluted Continuous Ops | 1.16 | 0.58 | 1.05 | 0.23 | 0.25 |
| EBITDA(a) | $4,129,000 | $2,376,000 | $2,595,000 | $1,915,000 | $2,198,000 |